期刊
JOURNAL OF INVESTIGATIVE DERMATOLOGY
卷 142, 期 2, 页码 435-444出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jid.2021.07.160
关键词
-
类别
资金
- Societe Francaise de Dermatologie
- La Ligue contre le cancer Grand Est
- association A Fleur de Peau
This study demonstrates the clinical relevance of anti-telomerase Th1 response in patients with melanoma, showing an inverse correlation with disease progression and a predictive factor of response to immunotherapy. The presence of anti-TERT Th1 response is associated with improved progression-free survival and overall survival.
CD4 T cells play a key role in anticancer immunity. In this study, we investigate the clinical relevance of circulating CD4 T helper type 1 (Th1) response against telomerase (anti-TERT Th1 response) in patients with melanoma. The spontaneous anti-TERT Th1 response was detected in 54.5% (85/156) of patients with melanoma before treatment. The prevalence of this systemic response was inversely related to Breslow thickness >1 mm and American Joint Committee on Cancer stage >= II (P = 0.001 and 0.032, respectively). In contrast to patients treated with targeted therapies, the anti-TERT Th1 immunity was associated with an objective response after immune checkpoint inhibitors treatment. Hence, 86% (18/21) of responder patients exhibited pre-existing anti-TERT Th1 versus 35% (6/19) in nonresponders (P = 0.001). This response was also associated with increased progression-free survival and overall survival in patients with melanoma treated with immune checkpoint inhibitors (P = 0.0008 and 0.012, respectively). Collectively, the presence of circulating anti-TERT Th1 response is inversely related to melanoma evolution and appears to be a predictive factor of response to immunotherapy. Our results highlight the interest in telomerase-specific CD4 Th1 response as a promising blood-based biomarker of immune checkpoint inhibitors therapy in melanoma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据